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The link between obesity and renal disease is unclear, and
there is no consensus as to whether obese individuals are at
increased risk for kidney disease after living kidney donation
if they otherwise meet acceptance criteria. We retrospectively
studied time-zero (implantation) biopsies in 49 obese (body
mass index (BMI)X30 kg/m2) and 41 non-obese (BMIo30 kg/
m2) renal donors that met acceptance criteria. We found that
our obese donor population had higher systolic blood
pressure (Po0.001 vs non-obese) and higher absolute
iothalamate clearance (P¼ 0.001 vs non-obese) before
donation. The obese donors had larger glomerular planar
surface area compared to non-obese controls (P¼ 0.017), and
this parameter correlated with patient weight and urinary
microalbumin excretion. Detailed examination of the biopsies
revealed that although most histologic findings were similar
between groups, the obese donors had more tubular dilation
(P¼ 0.01), but less tubular vacuolization (P¼ 0.02) than the
non-obese controls. There was also a trend toward more
arterial hyalinosis in the obese patients than controls
(P¼ 0.08). From these data, our studies detected subtle
differences in donor organs obtained from obese compared
to non-obese individuals. Further studies should be carried
out to quantify the long-term impact of these findings.
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Reports examining 10- and 20-year outcomes of living kidney
donors selected for normal weight and in excellent health
support the general safety of living kidney donation.1
However, the increasing shortage of deceased donor kidneys
and practical advantages associated with living donor kidney
transplants have led to wider consideration of living donors
previously considered too old, too heavy, or excluded owing
to elevated blood pressures. Obesity in kidney donors is
controversial because of the potential for both short- and
long-term complications. Pressures to examine this question
are rising as a result of rapidly increasing body weight over
the past decade in most Western populations. The long-term
risk of living with a solitary kidney is unknown for obese
donors. This group appears intuitively to be at increased risk
for the development of obesity-related comorbidities such as
diabetes, which may affect long-term renal function of the
donor. We recently reported that the perioperative complica-
tion rate and short-term renal function of obese donors is
similar to that of non-obese donors using current methods of
laparoscopic nephrectomy.2
We examined whether individuals without evident func-
tional abnormalities (reduced glomerular filtration rate or
proteinuria) who chose to donate a kidney may nonetheless
harbor undetected renal abnormalities. We hypothesized that
obesity might stimulate renal hypertrophy leading to
acceptable levels of glomerular filtration despite the presence
of occult renal disease. The aim of this study was to examine
the possibility of unrecognized pathologic changes in both
non-obese (body mass index (BMI) o30 kg/m2) and obese
(BMIX30 kg/m2) donors at the time of living donor
nephrectomy using detailed histologic and morphometric
analysis of baseline (implantation) allograft biopsies. We
report results of a series of obese and non-obese donors
undergoing donor nephrectomy between January 2000 and
March 2003.
RESULTS
Our study population consisted of 41 non-obese donors
(BMIo30 kg/m2) and 49 obese donors (BMIX30 kg/m2)
who donated kidneys to a spouse, relative, or friend. The
demographics for these groups are shown in Table 1. Both
groups had similar mean ages and similar distribution of
male and female subjects. The two groups of donors had
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similar height; however, as expected, there was a significant
difference in the groups as to their weight, and consequently
BMI. The pre-nephrectomy serum creatinine level was not
different between the non-obese and obese donors, with the
mean values being 1.270.2 and 1.070.1 mg/dl, respectively.
Microalbumin measured on 24 h urine collection was also
not different between the groups. The mean pre-donation
systolic blood pressure was higher in the obese donors than
in the non-obese donors (136715 vs 123713 mm Hg,
Po0.001), and there was a similar trend in diastolic blood
pressure with higher readings in obese donors (77710 vs
7379 mm Hg, P¼ 0.06).
The pre-donation renal function for the two groups is
shown in Figure 1. The left half of the figure shows the
absolute value of iothalamate clearance (ml/min) as median,
lower and upper quartile, and range. As a group, these values
were higher in the obese donors than the non-obese donors
(P¼ 0.001). When adjusted for body surface area (‘corrected’
iothalamate clearance (ml/min/1.73 m2)), there was no
difference between the two groups (P¼ 0.72).
Figure 2a–c show the scores assigned to the various
histologic features observed in time-zero biopsies obtained
from obese (BMIX30 kg/m2) and non-obese (BMIo30 kg/m2)
donors. The scores for intimal arteritis (v), tubulitis (t),
interstitial inflammation (i), and glomerulitis (g) are not
shown and, not surprisingly, the vast majority received scores
of ‘0’, and there were no significant differences between the
two groups. Shown in Figure 2a are the scores assigned to
glomerulopathy (cg), intimal thickening (cv), tubular
atrophy (ct), and interstitial fibrosis (ci) components of the
obese and non-obese donor’s time-zero biopsies. Only 9.8%
of donors had any fibrosis at baseline (all grade 1). Atrophy
of isolated tubules was common at time zero in both groups
of donors, occurring in 59.2% of obese donors (all grade 1)
and 53.6% of non-obese donors (all grade 1 expect one
patient). Intimal thickening was not uncommon on these
biopsies as well, 44.9% of obese donors had some intimal
thickening (all grade 1 except in four individuals with grade
2) compared with 43.9% of non-obese donors (all grade 1
except in two individuals with grade 2). Despite these
histologic findings, there were no differences in the distribu-
tion of scores between the obese and non-obese donors.
Other biopsy scores are shown in Figure 2b and c. There
was no mesangial matrix (mm) increase seen in either the
obese or non-obese donors. There was a greater incidence of
mild arterial hyalinosis noted in the obese donor biopsies
compared to the non-obese donor biopsies (44.9 vs 29.3%
(all grade 1), P¼ 0.08).Those donors with arterial hyalinosis
did not have a different systolic or diastolic blood pressure
when compared to donors without arterial hyalinosis
(P¼ 0.30 and 0.17, respectively). The incidence of tubular
vacuolization was higher in the non-obese donors compared
with the obese donors (68.3 vs 36.7% (all grade 1), P¼ 0.01).
These changes were predominately noted in the distal
tubules. Conversely, the incidence of tubular dilation was
higher in the obese donors than the non-obese donors (44.9
vs 22.0%, all grade 1, P¼ 0.02). The scores for segmental
sclerosis (P¼ 0.32), tubular casts (P¼ 0.43), interstitial
edema (P¼ 0.42), and endothelial cell swelling (P¼ 0.32)
did not differ between the groups. There was an increase in
Table 1 | Demographics and laboratory values in living kidney donors
Variablea Non-obese (N=41) Obese (N=49)
Age (years) 4079 (19–58) 43711 (19–67)
Gender (male:female) 15:26 20:29
Donor height (m) 1.7070.10 (1.49–1.87) 1.6770.08 (1.42–1.89)
Donor weight (kg) 72.2711.8 (50.8–95.3) 105.2717.6 (73.0–162.7)
Donor BMI (kg/m2) 24.872.2 (20.5–28.7) 37.675.0 (30.3–59.0)
Pre-donation serum Cr (mg/dl) 1.270.2 (0.8–1.4) 1.070.1 (0.8–1.4)
Pre-donation urine Microalbumin (mg/24 h) 7.977.9 (2.0–41.0) 8.475.1 (1.0–25.0)
Pre-donation systolic blood Pressure (mm Hg)b,* 123713 (100–153) 136715 (110–176)
Pre-donation diastolic blood Pressure (mm Hg)b,** 7379 (53–94) 77710 (54–106)
Abbreviations: BMI, body mass index; Cr, creatinine.
aMean7s.d. (range), except where noted.
bBlood pressure readings were at the initial evaluation, see text for details.
*Po0.001 (obese vs non-obese).
**P=0.06 (obese vs non-obese).
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Figure 1 | Pre-donation iothalamate clearance. The median, 25th
and 75th percentile values, and range are shown for the uncorrected
(left, in ml/min) and corrected iothalamate (right, in ml/min/1.73 m2)
clearances for the non-obese (N¼ 41, BMIo30 kg/m2) and obese
(N¼ 49, BMIX30 kg/m2) living kidney donors. There was a statistically
significant difference in the uncorrected values between the non-
obese and obese donors (P¼ 0.001); this difference disappeared
when standardized for body surface area (P¼ 0.72).
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glomerular hypertrophy in obese patients that approached
statistical significance (P¼ 0.06). When we tabulated the
percentage of glomeruli that were globally sclerotic, the
median (range) was 0.0% (0.0–20.0%) for the non-obese
donors and 3.0% (0.0–17.6%) for the obese donors
(P¼ 0.58). By light microscopy, the estimated cortical
fibrosis (%) was not different between the groups (non-
obese vs obese, 371 vs 371%, P¼ 0.28).
In addition to general histologic changes, we specifically
determined glomerular size in both groups of biopsies. Of the
90 donors selected for this study, 10 did not have glomeruli
suitable for measuring the glomerular planar surface area
(GPSA) owing to lack of a clear vascular pole. This left 80
donors with GPSA data available (N¼ 38 with BMIo30 kg/m2
and N¼ 42 with BMIX30 kg/m2). The number of glomeruli
(mean7s.d. (range)) measured in the non-obese group was
1778 (3–37) compared to 21713 (1–43) in the obese group
(P¼ 0.08). Figure 3 compares the median, lower/upper
quartile, and range of GPSA for the non-obese and obese
donors. The mean GPSA was significantly greater in obese
donors compared to non-obese donors (23 604 vs
20 878 mm2, P¼ 0.017).
There was a correlation between donor weight and GPSA
(Figure 4a, Pearson r¼ 0.25, P¼ 0.023), and a correlation of
the log (microalbumin) with GPSA (Figure 4b, Pearson
r¼ 0.34, P¼ 0.003). The correlation between the mean GPSA
and donor BMI also approached statistical significance (data
not shown, Pearson r¼ 0.20, P¼ 0.08). There was no
correlation between the uncorrected iothalamate clearance
and mean GPSA (Pearson r¼ 0.16, P¼ 0.18), or the
corrected iothalamate clearance and mean GPSA (Pearson
r¼0.02, P¼ 0.84).
The median follow-up after donation was 340 days (range
21–963 days). At this time, the serum creatinine was
1.370.2 mg/dl (N¼ 60 donors), and the serum creatinine
in non-obese donors was similar to that in the obese donors
(1.470.2 vs 1.370.2, P¼ 0.83). The uncorrected iothalamate
clearance was 80719 ml/min and the corrected iothalamate
clearance 69714 ml/min/1.73 m2 (N¼ 44 donors). The
uncorrected iothalmate clearance was significantly lower in
the non-obese patients compared to the obese (71715 vs
87719, P¼ 0.004), and the corrected values at follow-up
were lower in the non-obese donors compared with the obese
group (65712 vs 72715, P¼ 0.05). Follow-up microalbu-
min excretion was only available in 36 donors, and was
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Figure 2 | Histology scores for renal biopsies. (a) Banff ’97 chronic
scores in non-obese and obese donors. The distribution of chronic
Banff 97 scores for the time-zero biopsies in non-obese and obese
donors is shown. The scores are shown as percentage of the total
number of kidney donors (N¼ 41 non-obese and N¼ 49 obese) (cg,
glomerulopathy; cv, fibrous intimal thickening; ct, tubular atrophy;
ci, interstitial fibrosis). (b) Other time-zero biopsy scores in non-obese
and obese donors. The distribution of other biopsy scores for the
time-zero biopsies in non-obese and obese donors is shown. The
scores are shown as percentage of the total number of kidney donors
(N¼ 41 non-obese and N¼ 49 obese). There are significant differ-
ences in the scores for tubular vacuolization (P¼ 0.01) and tubular
dilation (P¼ 0.02) between the groups. (mm, mesangial matrix
increase; ah, arterial hyalinosis). (c) Time-zero biopsy scores in non-
obese and obese donors (continued). The distribution of other biopsy
scores for the time-zero biopsies in non-obese and obese patients is
shown. The scores are shown as percentage of the total number of
patients, N¼ 41 non-obese and N¼ 49 obese kidney donors. There
are no significant differences between these groups (see text for
details).
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Figure 3 | GPSA – non-obese vs obese donors. The median, 25th,
and 75th percentile values, and range are shown for GPSA (mm2) for
non-obese (N¼ 42) and obese (N¼ 39) kidney donors. The difference
between these groups is statistically significant (mean (non-obese vs
obese) 20 878 vs 23 604 mm2, P¼ 0.017).
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9710 mg/24 h with no difference between the non-obese and
obese donors (11715 vs 874 mg/24 h, P¼ 0.24).
DISCUSSION
A major purpose of the living donor kidney evaluation is
to exclude clinical kidney disease. The relationship
between functional studies and histopathologic features in
otherwise healthy obese individuals is not well established.
One potential value of examining biopsy material is
to provide a basis for anticipating the long-term impact of
donor nephrectomy. The current study failed to demonstrate
occult renal disease such as glomerulopathy on time-
zero biopsies in any of the obese donors who met our
selection criteria. However, these results did demonstrate
subtle pathologic changes that were more pronounced in
obese donors. These pathologic changes were found in
donors with normal albumin secretion and normal renal
function.
The significance of these pathologic changes is unknown.
We found no differences in glomerulopathy (cg), intimal
thickening (cv), tubular atrophy (ct), and interstitial fibrosis
(ci) scores for these two groups. Our group has previously
reported that baseline mild fibrosis and tubular atrophy is
present in a small percentage of living donor kidneys.3 We
detected an increase in the prevalence of mild hyalinosis in
the time-zero biopsies of obese donors compared to non-
obese donors. Although the cause and significance of mild
hyaline deposition in kidneys is not known, hyalinosis has
been associated with hypertension and increased age. It
should be noted that we analyzed only initial blood pressure
readings here; all donors with elevated readings underwent
further testing using 18 h ambulatory blood pressure
monitoring before acceptance (data not shown). However,
we did not demonstrate more hyalinosis in donors with
elevated systolic blood pressure. The finding that a third of
non-obese donor kidneys demonstrated hyalinosis supports a
cause owing to factors other than obesity. Morphometric
vascular dimensional analysis of implantation biopsies from a
different donor cohort suggests that thickening of vascular
wall layers is related mainly to donor age.4
The significance of increased tubular dilation in obese
donor biopsies and the increase in tubular vacuolization in
the non-obese donor biopsies is unclear. To our knowledge,
these pathologic findings have not been systematically
studied in renal biopsies. We can only speculate on the
etiology of these changes and are currently examining them
further in a larger, retrospective study of transplant biopsies
at our institution. Clearly, despite a rigorous selection
protocol utilizing age-specific cutoffs for measured iothala-
mate clearance and urinary microalbumin excretion, we do
find time-zero biopsies with pathologic changes; but the
impact of these findings requires further study across a large
population of donors. We recommend the systematic
evaluation of time-zero biopsies by all institutions as a
marker for donor selection and as a variable in the analysis of
transplant outcomes.
Obese donors had greater mean GPSA in our study.
Assuming that this translates into larger mean glomerular
volume, these results confirm that larger body mass was
associated with larger glomeruli in humans. GPSA measure-
ments did not correlate with BMI or glomerular filtration
rate but did correlate with donor weight and urinary
microalbumin secretion. Numerous studies have shown that
urine microalbumin is a predictor for future renal disease
and mortality in diabetics, hypertensives, and the general
population.5–7 Formal morphometric assessment of the
thickness of the glomerular basement membrane and the
mesangial fractional volume – two measurements that may be
associated with early glomerular disease were not performed
in our study.8 Whether increased microalbuminuria in a
renal donor portends a shorter life of the transplanted kidney
or poor function cannot be ascertained from our current
study, which was restricted to donors with normal urinary
microalbumin excretion. Whether donors who have elevated
urinary microalbumin secretion should be allowed to donate
due to a potential risk for increased cardiovascular morbidity
is not known.
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Figure 4 | GPSA correlations. (a) GPSA as a function of body weight.
The correlation between GPSA (mm2) and patient weight (kg) is
shown. A weak but significant relationship was noted (Pearson
r¼ 0.25, P¼ 0.023) between these variables. As discussed in the text,
GPSA did not correlate with BMI (kg/m2). (b) GPSA as a function
of log (microalbumin). The correlation between the log of the
pre-donation microalbumin excretion and BMI is shown. There was a
good correlation of these two variables (Pearson r¼ 0.34, P¼ 0.003).
GPSA was correlated with the left censored microalbumin values
using the method of Lynn.18
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Although obesity increases the risk for later development
of conditions such as diabetes and hypertension, which may
in turn affect renal function, the impact of obesity alone on
the development of renal disease remains poorly defined.9
The earliest lesions associated with obesity-related glomer-
ulopathy (ORG) have not been identified. ORG was noted by
Weisinger et al.10 in association with focal segmental
glomerulosclerosis and nephrotic range proteinuria in
massively obese patients. Although the prevalence and
long-term clinical significance of this lesion remains poorly
defined, a series reported by Kambham et al.11 notes an
increased incidence of this lesion in 0.2% of all biopsies
received during 1986–1990 rising to 2.0% of biopsies received
during the period of 1996–2000. When compared to a
matched series of patients with focal segmental glomerulo-
sclerosis at a mean follow-up of 27 months, patients with
ORG were less likely to have nephrotic range proteinuria, less
likely to double their creatinine, or progress to end-stage
renal disease. Histologic findings of ORG noted in this series
included increased glomerular size when compared to age-
and gender-matched controls (measured by diameter) in
association with more severe arteriolosclerosis, but fewer
sclerotic glomeruli and less effacement of foot processes when
compared to control patients with focal segmental glomer-
ulosclerosis. The important difference is that the biopsies in
our series came from donors who had excellent renal
function and normal microalbumin excretion, whereas the
biopsies reviewed in Kambham’s series were performed
owing to clinical evidence of renal dysfunction. The mean
age in our series was higher, so it is unlikely that our subjects
were accepted before the development of either proteinuria
or sclerosis.
Two important questions posed by our current study are
whether glomerulomegaly without sclerosis seen in the obese
donor portends future renal dysfunction and whether
unilateral nephrectomy has any impact upon this process.
The impact of nephrectomy on the development of ORG or
any other type of renal pathology in the remaining kidney,
regardless of glomerular size at baseline, is unknown. There
are no reported biopsy series in donors with larger glomeruli
following nephrectomy. Long-term studies on donor out-
comes do suggest a very low incidence of renal dysfunction.
However, Praga et al.12 have reported an increased incidence
of proteinuria and renal insufficiency developing many years
later in obese patients undergoing nephrectomy for non-
malignant disease when compared to non-obese patients. It is
unclear whether these findings apply to our donor popula-
tion.
Whole kidney renal mass and specific renal dimensions
were not measured in our study and measurement of the
glomerular number per kidney was also not possible in these
specimens. It could be hypothesized that the relative
hyperfiltration of obese donor kidneys (increased iothalamate
clearance) may stem from a relative deficit of renal mass and
nephrons. It has been suggested that ‘nephron dosing’ may
play a pathogenic role in the development of hypertension
and progression of renal damage.13 It may be that
hyperfiltration in our obese donors precedes the development
of an eventual renal injury (as in stage I diabetic nephro-
pathy), and this may serve as a predictor of poor long-term
outcome. Future areas of investigation should focus on long-
term follow-up of obese donors to determine if increased
glomerular size will impact renal function. In addition,
morphometric and histologic analysis of allograft biopsies
obtained serially following transplantation from donors with
glomerulomegaly may be useful to further elucidate the
significance of these lesions. Decreased allograft function in
recipients with a time-zero biopsy demonstrating increased
glomerular size has been reported, although donor weight
was not investigated and the majority of the kidneys came
from deceased donors.14
Although the current epidemic of obesity has negative
effects on long-term health of those affected, risk to the
potential obese donor who is otherwise in excellent health
remains unclear. As would be predicted by normal pre-
operative evaluation of renal function, there were no donors
with evidence of even mild glomerulopathy. However, obese
donors did have an increased glomerular filtration rate, an
increased prevalence of mild hyalinosis and tubular dilation,
and increased glomerular size compared to non-obese
donors. Although the advent of the laparoscopic technique
has made donor nephrectomy safe and technically feasible in
obese individuals, careful preoperative evaluation and
continued donor follow-up will be necessary to determine
the long-term impact of donor nephrectomy on obese living
kidney donors.
MATERIALS AND METHODS
This study was carried out with informed consent using a protocol
approved by the Mayo Foundation Institutional Review Board.
Potential living donors were evaluated according to accepted donor
guidelines as part of the Mayo Clinic, Rochester Kidney/Pancreas
transplant program, which included a thorough history study,
physical examination, and laboratory evaluation as previously
described.15 Specific acceptance criteria during this period included
limiting microalbumin excretion to less than 30 mg/day and fasting
blood glucose levels to less than 110 mg/dl. Blood pressure
evaluation included ambulatory BP monitoring.16 Obesity was not
considered an absolute contraindication, although patients were
encouraged to lose weight before donation and to maintain a
weight-loss program after donation. During the time period of this
study, approximately 38% of accepted living donors were obese.
Proteinuria or microalbuminuria was the main reason for denial in
11% of obese individuals not approved for donation compared to
7% of non-obese (BMIo30 kg/m2) denied donor candidates. After
donation, follow-up examinations at our institution were encou-
raged but not required; as available, we did extract serum creatinine,
iothalamate clearance rates, and 24 h microalbumin excretion from
the most recent data in the medical record.
For this study, we selected obese kidney donors from a
prospectively maintained database of all donor/recipient renal
transplant pairs performed at our institution. The database was
also queried to retrieve non-obese donors of the same gender and
similar age to the obese donors, in order to control for these effects
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in the pathologic analysis. We selected only kidney donors where the
recipient had undergone a time-zero protocol biopsy as part of our
comprehensive follow-up. The time-zero (implantation) biopsy is
performed after the completion of the vascular and ureteral
anastomoses during the recipient surgery (approximately 30 min
after reperfusion). Two 18-gauge core needle biopsies are obtained
using an automated biopsy gun.
The time-zero biopsies were reviewed in a blinded fashion by a
pathologist with extensive experience in renal biopsy interpretation.
The biopsies were permanently fixed in paraformaldehyde and
examined using hematoxylin and eosin, periodic-acid Schiff, and
trichrome-stained sections. Routine immunohistochemistry and
electron microscopy were not performed. These biopsies were scored
using the 10 standardized Banff 97 criteria and the following
additional criteria: glomerular hypertrophy, segmental or global
glomerular sclerosis, tubular dilatation, tubular vacuolization,
tubular casts, interstitial edema, and endothelial cell swelling.17 All
additional criteria were scored in a similar fashion to the Banff 97
pathologic classification, namely on a 0, 1, 2, 3 scale – reflecting
none, mild, moderate, and severe changes. Additionally, the
percentage of renal cortical surface area with fibrosis was estimated
by the pathologist.
Morphometric analysis of glomerular size was performed in a
blinded fashion by a single investigator. The periodic acid-Schiff
stained slides (two per case) were examined and all glomeruli
exhibiting a clear vascular pole were electronically captured as a JPG
file at  400 using MetaVueTM software (v5.0). At a later session, the
glomeruli were outlined using the same software and the resulting
GPSA was converted from arbitrary square pixels into square
microns (mm2) using a calibrated standard. The mean and standard
deviation were calculated for each donor. Based on repeated
measurements of the glomeruli, the reproducibility of the GPSA
measurements was within 5%.
SAS software (version 8.0, SAS Institute, Cary, NC, USA) was
used for the statistical analyses. All continuous variables are reported
as the mean7s.d. Comparisons between the groups were performed
using the Student’s t-test with the Satterthwaite correction.
Correlations for most variables were performed using Pearson’s
method. The data for microalbumin are left-censored (e.g. the
values fall below a level of detection that varied over time) and
correlations were made using the method of Lynn.18 All P-values of
less than 0.05 are considered statistically significant.
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